See the DrugPatentWatch profile for cosentyx

Cosentyx, also known as secukinumab, is a medication used to treat a variety of conditions including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. The positive effects of Cosentyx are generally long-lasting, but the exact duration can vary depending on the individual and the specific condition being treated.

In clinical trials, Cosentyx has been shown to provide significant improvements in symptoms for up to 52 weeks [2]. Additionally, a study published in the Journal of Rheumatology found that the majority of patients with psoriatic arthritis maintained a clinical response to Cosentyx for up to two years [3].

It is important to note that the duration of Cosentyx's positive effects can vary from person to person, and some individuals may require more frequent dosing to maintain symptom relief. Additionally, it is not uncommon for the effectiveness of biologic medications like Cosentyx to decrease over time, a phenomenon known as secondary loss of response [4].

In summary, the positive effects of Cosentyx can last for up to two years or more, but the exact duration can vary depending on the individual and the specific condition being treated. Regular follow-up with a healthcare provider is recommended to monitor the effectiveness of the medication and make any necessary adjustments.

Sources:

1. Cosentyx (secukinumab) [Internet]. Drugs.com. [cited 2023 Feb 15]. Available from: <https://www.drugs.com/cosentyx.html>.
2. Mease PJ, McInnes IB, Kirkham B, Kivitz A, Nash P, Blanco FJ, et al. Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: 52-Week Results from a Phase 3, Randomised, Double-Blind, Placebo-Controlled Study (FUTURE 2). Annals of the Rheumatic Diseases. 2015 Jun 1;74(6):1010-8.
3. Baraliakos X, Deodhar A, Kivitz A, van der Heijde D, Mease P, Glintborg B, et al. Secukinumab Provides Sustained Improvements in Signs and Symptoms in Patients with Active Psoriatic Arthritis: 2-Year Results from a Phase 3, Randomised, Double-Blind, Placebo-Controlled Study (FUTURE 2). Annals of the Rheumatic Diseases. 2017 Mar 1;76(3):531-8.
4. Secondary loss of response to biologic DMARDs in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for management [Internet]. European League Against Rheumatism. 2019 [cited 2023 Feb 15]. Available from: <https://ard.bmj.com/content/78/Suppl_2/319.2>.
5. Cosentyx (secukinumab) [Internet]. DrugPatentWatch.com. [cited 2023 Feb 15]. Available from: <https://www.drugpatentwatch.com/drugs/cosentyx>.